STUDY QUESTION: Do the chemotherapeutic regimens of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) or OEPA-COPDAC (combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)) used to treat Hodgkin lymphoma (HL), affect the density, morphology and in vitro developmental potential of human ovarian follicles?
samples there was very limited development to the secondary stage, whereas in untreated samples from lymphoma patients growth was similar to that observed in obstetric tissue (untreated; P < 0.01 versus ABVD-treated, NS versus obstetric).
LARGE SCALE DATA: N/A LIMITATIONS, REASONS FOR CAUTION:
Although a large number of follicles were analysed, these data were derived from a small number of biopsies. The mechanisms underpinning these observations have yet to be determined and it is unclear how they relate to future fertility.
Introduction
The number of follicles in the ovary decreases progressively with age. Treatments such as some chemotherapy agents can accelerate this loss leading to premature ovarian insufficiency (POI) with loss of fertility and estrogen deficiency in female survivors of cancer (Morgan et al., 2012) . The likely range of mechanisms of drug-induced ovarian damage has yet to be fully characterized but includes direct damage to growing and non-growing follicles (NGFs), and loss of growing follicles may lead to the recruitment of dormant follicles to the growing phase, which in turn are lost, thus accelerating the depletion of the nongrowing pool, i.e. the ovarian reserve (Meirow et al., 2010; Morgan et al., 2012; Kalich-Philosoph et al., 2013) .
Since the mid-1970s the standard first-line treatment for early stage Hodgkin lymphoma (HL) in many countries has been adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) (Bonadonna and Santoro, 1982; Meirow and Nugent, 2001; Meyer et al., 2012) . Early stage HL patients receiving ABVD-based treatment where involved field radiotherapy does not include that the ovaries have a good reproductive prognosis for both fertility and risk of POI (Hodgson et al., 2007 , Swerdlow et al., 2014 . In contrast, advanced stage HL patients treated with a drug regimen containing one or more alkylating agents and involved field radiotherapy have a higher prevalence of POI (Behringer et al., 2005) and should therefore be considered for fertility preservation strategies before commencing treatment .
The purpose of this study was to examine microscopically, ovarian tissue from patients with lymphoma exposed to ABVD chemotherapy and compare this with samples exposed to the combined alkylating chemotherapeutic regime (OEPA-COPDAC) (combined vincristine, etoposide, prednisone, doxorubicin (OEPA) and cyclophosphamide, vincristine, prednisone, dacarbazine (COPDAC)), with samples not previously exposed to chemotherapy and with further samples from healthy women to determine whether follicle density, morphology and in vitro developmental potential were affected by these chemotherapeutic interventions. Comparing follicle densities across treatments requires identification of changes to NGF cortical densities in comparison with those predicted by age-related models (Kelsey and Wallace, 2012; Kelsey et al., 2013) . In this study, we used a recently reported validated age-related model of mean follicle density (MFD) in the ovarian cortex (McLaughlin et al., 2015) , to compare observations of MFD in tissue obtained after different chemotherapy regimens.
Materials and Methods

Patient selection
Diagnosis, patient age, chemotherapeutic regimen, anti-Müllerian hormone (AMH) concentrations and time between completion of treatment and biopsy collection are detailed in Table I .
Ovarian cortical tissue
Ovarian biopsies were obtained laparoscopically from six adolescents and seven adults diagnosed with HL and one adult diagnosed with non-HL. All patients were undergoing removal of ovarian cortex for fertility cryopreservation either prior to chemotherapy or following relapse of previously treated illness. Protocols for tissue donation for research had Ethical Committee approval from South East Scotland Research Ethics Committee (ref 06/S1103/26), and all patients gave informed consent in writing. The mean patient age was 20.2 ± 1.5 years (mean ± SEM) with a range of 12.0-30.0 years. For analyses, patients were divided into 3 groups: those treated with ABVD (aged 16-29 years, n = 8), those treated with OEPA-COPDAC (aged 14 -16 years, n = 3) and untreated patients or controls (aged 12-30 years, n = 3). Data were compared with results obtained from contemporaneous ovarian biopsies obtained from adult women undergoing elective Caesarean section (age range 23-39 years, n = 12) prepared and processed in an identical manner, also obtained with written informed consent and ethical committee approval (ref 10/S1101/24).
Tissue preparation and processing
Fresh ovarian biopsies (ranging in size from 8 x 5 mm and 6 x 4 mm all with variable thickness) were transported to the laboratory in holding medium (Leibovitz medium, Gibco; Life Technologies, Paisley, Renfrewshire, UK, supplemented with 2 mM sodium pyruvate, 2 mM L-glutamine, 3 mg/ml human serum albumin, 75 mg/ml penicillin G and 50 mg/ml streptomycin; all chemicals from Sigma-Aldrich, Poole, UK). The tissue was transferred into fresh pre-warmed (37 o C) holding medium and examined under a dissecting light microscope. A scalpel and fine forceps were used to remove any damaged or haemorrhagic areas as well as any tissue adhering to the underside of the biopsies to leave only intact cortex in place. Using a scalpel the tissue was divided into fragments of~4 x 2 x 0.5 mm; the number of fragments varied between biopsies. Fragments were fixed in 10% neutral buffered formalin (NBF) for 48 h, then processed and prepared for staining and microscopic evaluation as previously described .
Thawing of cryopreserved tissue
Two of the biopsies were cryopreserved by slow freezing (Gosden et al., 1994) and were donated for research at the patients' request. Tissue was thawed as described previously , inspected, divided into fragments, fixed and processed for staining and analysis as described above.
Assessment of MFD in ovarian biopsies
Each histological section of every tissue fragment was examined under light microscopy. Follicles were categorized according to their stage of development as previously described (Telfer et al., 2008; McLaughlin et al., 2014) .
To avoid over-counting, only follicles containing the nucleolus were assessed. The volume of tissue analysed per patient was calculated as described previously (Lass et al., 1997; Anderson et al., 2014) . Briefly, tissue volume was calculated as the sum of the area in square millimetre of all tissue sections analysed per patient, multiplied by 0.006 mm (the thickness of the sections) to give a value in cubic millimetre. The area of each section was measured, and MFD was determined by dividing the total number of follicles per patient by the volume of tissue analysed in cubic millimetre .
Evaluation of histology
Evaluation of the tissue sections was performed blinded to the treatment groups. Follicles in freshly fixed and cultured tissue pieces were categorized by developmental stage based on morphology as previously described . Follicle morphological normality was determined by an assessment of the appearance of the oocyte and surrounding cells using the cross-section containing the nucleolus as described previously Telfer, 2010, McLaughlin et al., 2014) . The presence of biovular and binucleate follicles was also noted. The spatial relationship between follicles was also assessed and classified as (i) single, i.e. no follicles within 15 µm of the follicle being evaluated, (ii) in close proximity, i.e. at least one other follicle occurring within 15 µm of the follicle being evaluated or (iii) direct contact, i.e. where two or more follicles appeared to share the same basal lamina or the basal laminae of two or more follicles abutted. Follicles were classified as occurring in clusters if five or more follicles were found in direct contact or close proximity. The presence of naked oocytes with few or no surrounding cells was also noted.
Fragment culture
Prior to fixation, a number of tissue fragments were selected at random from a subsection of the ABVD-treated patients (n = 4; age range 23-29 years), one OEPA-COPDAC-treated patient (16 years), two untreated controls (15 years and 30 years) and from obstetric patients (n = 10; age range 23-36 years). Between two and six fragments were obtained for each patient, prepared for culture and incubated for 6 days, then processed for histological evaluation as previously described .
Immunohistochemistry
A number of ABVD-treated, OEPA-COPDAC-treated and control tissue fragments fixed in NBF and embedded in paraffin as described previously were selected at random and cut in 6 µm sections and mounted on charged slides to investigate the expression of the germline marker protein DEAD box polypeptide 4 (DDX4). Antigen retrieval was performed using 0.01 M sodium citrate and endogenous peroxidase activity quenched by 3% hydrogen peroxide in methanol. Tissue sections were incubated in anti-DDX4/MVH ab13840 polyclonal primary antibody (Abcam, Cambridge, UK) overnight at 4 o C. Negative controls were established by replacing the primary antibody with goat serum. On completion of incubation, sections were washed and probed with anti-rabbit secondary antibody labelled with horseradish peroxidase for 30 min (ABC-Elite Rabbit IgG, Vectastain Elite Kit, PK-6101; Vector Laboratories Ltd, Peterborough, UK). DDX4 was detected using 3, 3′-diaminobenzidine peroxidase substrate kit (Vector Laboratories Ltd). Structures were positively identified as germ cells when brown staining was observed within a cell.
Statistical analysis
Observed mean follicle densities were compared to predicted mean follicle densities using an age-related model of MFD in the cortex of the human ovary (McLaughlin et al., 2015) . Chi-square Goodness-of-Fit analysis was used to test the null hypotheses that the observations matched predicted MFD. Pearson's product-moment correlation coefficients were also calculated to compare data to the line of identity where predictions exactly match observations. Due to the need for high confidence in the significance of any observed differences between predicted and observed densities, statistical significance was set at the 99% level throughout. Bland-Altman analysis was used to estimate the number of SD away from agreement between observations and predictions using the limits of agreement reported in McLaughlin et al. (2015) .
Results
Follicle density
The number of follicles and their developmental stage were determined by examining fresh and post-thawed fixed ovarian tissue from 14 previously treated and untreated lymphoma patients and an agematched group of 12 obstetric patients; a total of 6877 follicles were examined. The total number of follicles counted in each group and the volume of tissue analysed are shown in Table II . Ages and MFDs for the three groups of lymphoma patients are shown in Fig. 1A , together with age-related predictions taken from McLaughlin et al., (2015) . For the three patients who received no chemotherapy, we have insufficient evidence to reject the null hypothesis that the observed values for MFD are a perfect fit with predicted values taken from the agerelated model derived from data from other subjects receiving no chemotherapy: Chi-square P-value = 0.07; Pearson's productmoment correlation coefficient = 0.999 (P < 0.01, Fig. 1B ) with the observations within 1.25 SD of agreement between observed and predicted values (Fig. 1C) . The three patients who received OEPA-COPDAC chemotherapy had significantly lower observed MFD than predicted: Chi-square P-value < 0.01; Pearson's product-moment correlation coefficient = −0.399 (P = 0.74, Fig. 1B ) with the observations between 0 and 11 SD lower than the predictions (Fig. 1C) . However, the eight patients who had received ABVD chemotherapy had higher numbers of NGFs (160-303/mm 3 ) compared with samples from healthy women (8-46/mm 3 ) ( Table II ). The ABVD group had significantly higher value observed than predicted MFD: Chi-square P-value < 0.001; Pearson's product-moment correlation coefficient = 1.57 (P = 0.71, Fig. 1B ) with observations between 9 and 21 SD higher than the predictions (Fig.1C) . patients having tissue collected within 6 weeks and all OEPA-COPDAC patients undergoing biopsy within 9 months of treatment.
No correlation was found between the time interval and the MDF observed in tissue treated with either regimen: the marked increase in MFD in ABVD-treated tissues was observed in biopsies taken within 4 weeks of chemotherapy completion and was also present in samples taken up to 36 months after treatment, although the small sample size at the later treatment times does not allow for time after treatment to be robustly tested. The OEPA-COPDAC tissue from two out of three patients showed follicle numbers below that predicted at 6-9 months post-treatment. Biopsy tissue was only available from each patient at one time point; therefore, it was not possible to investigate by histological means whether deterioration or recovery of NGF density occurred over time.
Follicle categorization
The majority of all follicles observed in fixed tissue were non-growing irrespective of illness, treatment or age ( Fig. 2A) . However ABVD-treated tissue contained a significantly smaller percentage of growing follicles (3.0%) compared to untreated, OEPA-COPDAC-treated and obstetric patients (15.6%, 21.4% and 18.0% respectively; P < 0.001) ( Fig. 2A) . Analysis of oocyte appearance showed that in biopsies collected from untreated, ABVD-treated and obstetric patients, morphological normality was high with >74% of oocytes appearing normal. In contrast, less than half of the oocytes in follicles observed in OEPA-COPDAC-treated tissue met the criteria for normality (41.9% in OEPA-COPDAC compared to 76.8% in untreated; 78.4% in ABVDtreated and 74.2% in obstetric samples; P < 0.001) (Fig. 2C and D) . . The solid horizontal line shows no trend between means and differences. Blue dots denote difference from predicted MFD for untreated patients; these are between 0 and 1.25 SD (i.e. between 0 and 16 follicles) below the zero predicted difference. Greens dots denote difference from predicted MFD for three OEPA-COPDAC-treated patients' chemotherapy protocol; these are between 1 and 11 SD (i.e. between 12 and 132 follicles) below the zero predicted difference. The red dots denote difference from predicted MFD for eight ABVD-treated patients; these are between 9 and 21 SD (i.e. between 108 and 250 follicles) above the zero predicted difference.
Follicle development in cultured tissue
To investigate the in vitro developmental potential of chemotherapyexposed follicles, tissue fragments from a subset of patients representing each group were cultured for 6 days. It was not possible to culture fragments from every patient due to the limited amount available. A total of 89, 614 and 274 follicles were analysed in cultured tissue obtained from untreated (n = 2), ABVD-treated (n = 4) and obstetric patients (n = 10), respectively. Analysis of cultured tissue fragments from two patients treated with OEPA-COPDAC has been omitted due to extreme follicle degeneration in both patients. Initiation of follicle growth was observed in all of the three remaining groups. Post-culture, the proportion of growing follicles was 19.9% in ABVDtreated tissue, 41.6% in untreated tissue and 46.3% in obstetric samples (all P < 0.001 versus uncultured) (Fig. 3A) . Development to the secondary stage occurred in both untreated and obstetric groups with 18% and 18.2% of follicles observed reaching this stage, respectively, whereas very few follicles progressed in the ABVD-treated tissue,comprising only 1.2% of follicles at the secondary stage after culture ( Fig. 3B and C) .
Immunohistochemical localization of DDX4
Due to the high density of NGFs observed in ABVD-treated tissue and the presence of clusters, biovular and binucleate follicles, immunohistochemistry was performed to examine whether the germline marker DDX4 could be localized in these structures. Uncultured tissues sections from nine patients representing all groups were studied; the number of sections per patient was variable due to tissue availability, and the number of follicles per section was also highly variable. Discrete positive DDX4 staining was observed in oocytes of follicles at all stages of development in all groups. DDX4 was also localized to the biovular and binucleate oocytes and clusters of naked oocytes with adjacent or shared oolemma observed in ABVD-treated tissue. No positive staining was observed in any tissue sections where the primary antibody had been omitted (Fig. 3D ).
Spatial distribution of follicles
In all groups, individual follicles and groups of follicles were distributed unevenly throughout the cortex; however, the pattern of distribution varied between groups with the majority of follicles occurring discretely (single follicles ≥ 15 µm apart) in obstetric tissue ( Fig. 4A and  B) . ABVD-treated and untreated adolescent tissues appeared markedly different from the others examined, with significantly fewer discrete follicles seen and clusters of closely packed follicles (five or more NGF ≤ 15 µm apart) observed in these groups (P < 0.05; ABVDtreated and untreated versus OEPA-COPDAC-treated and obstetric patients) (Fig.4A and C) . Biovular and binucleate follicles were observed in ABVD-treated tissues and also in the 12-year-old untreated patient's tissue comprising between 8% and 18% of the NGF population. These structures were not observed in the other tissues examined. Follicle clusters often contained naked or partially naked oocytes, which otherwise appeared morphologically normal (Fig 4C) .
Discussion
Ovarian dysfunction and reduced fertility potential can be a consequence of cytotoxic therapy particularly where alkylating agents have been used, with resultant loss of the ovarian reserve (Meirow et al., 2010) . In contrast, women diagnosed with lymphoma and treated with the gonad-sparing regimen ABVD have a low risk of significant impairment of fertility (Hodgson et al., 2007) or of POI (Swerdlow et al., 2014) , and no reduction in follicle numbers have been observed (Seshadri et al., 2006) . The impact of chemotherapy on the ovarian reserve is evaluated indirectly by clinical parameters including amenorrhoea, AMH and FSH levels (Meirow, 2000; Oktay et al., 2006; Anderson and Cameron, 2011) . Post-treatment AMH levels in lymphoma patients clearly show the differential impact of ABVD and alkylating agent-based regimens (Decanter et al., 2010) , and AMH levels may also be reduced at the time of diagnosis (Lawrenz et al., 2012) . Although early studies showed that chemotherapy reduced the number of antral follicles in the ovary in girls treated for leukaemia (Himelstein-Braw et al., 1978) ; this is the most detailed quantitative analysis of the direct effect of chemotherapy treatment on density of the ovarian reserve in lymphoma patients and the impact of the different chemotherapy regimens on morphology and in vitro developmental potential of follicles. In this study, we have identified and quantified differences in the NGF population of treated and untreated lymphoma patients. The observed MFD of untreated lymphoma patients were close to the densities predicted by an age-related model indicating that the disease itself is not implicated in the variations of the ovarian reserve observed in the chemotherapy-treated groups.
Treatment regimens containing alkylating agents such as cyclophosphamide are known to lead to POI via a direct or indirect reduction in the NGF population (Meirow, 2000; Oktem and Oktay, 2007; Meirow et al., 2010) . Our finding that patients treated with the OEPA-COPDAC regimen had lower than predicted MFDs confirms and quantifies this, although the MFD in this small group varied from very low to close-to-average for age. Further analysis of the degree of loss is not possible without knowing pretreatment values. In this study, patients treated with OEPA-COPDAC were all teenagers (14, 15 and 16 years) at the time of tissue collection, which was 6-9 months after completion of chemotherapy. Of the three patients included in this study treated with OEPA-COPDAC, one was diagnosed with reduced ovarian reserve based on having regular menstrual cycles but undetectable AMH levels 1 year after completion of treatment and another was diagnosed with POI 6 years post-chemotherapy.
Surprisingly, we found a striking and statistically highly significant increase in follicle number and MFD after ABVD chemotherapy. All eight ABVD patients had higher follicle counts (Table II) and a markedly higher follicle density than predicted (Fig. 2C) . Despite the well reported variation of follicle density between and within human cortical biopsies follicles (Kohl et al., 2000; Qu et al., 2000; Poirot et al., 2002; Schmidt et al., 2003; McLaughlin et al., 2015) , all ABVD-treated samples consistently showed an increase in the NGF population, whereas this was not seen for any of the other groups or individual biopsies. We initially considered that this increase might be attributed to a reduction in ovarian volume during treatment as all treatments would result in an initial reduction in ovarian volume because of the loss of large follicles. However, MFD is based on volume of ovarian cortex, not whole ovary and there is no evidence to support a differential effect on ovarian cortex volume by any treatment. Additionally, these samples were collected 4 weeks to 36 months after the completion of treatment with resumption of follicular growth (indicated by regular menses) in those with longer intervals, and there was no apparent relationship between increased follicle number/MFD and interval since treatment. The observed differences between ABVD MFD and control data is between 9 and 21 SD ( Figure 1C ), and so a reduction in cortical volume would need to be of that order of magnitude. There are no clinical data/observations to support such a degree of shrinkage.
The underlying mechanism for an increase in MFD after ABVD treatment remains to be established. An alternative explanation may be that this treatment has resulted in new oocytes/follicles being formed. Putative germline stem cells or oogonial stem cells, which may be capable of regenerating the NGF population under perturbed conditions have been identified within the adult human ovary (White et al.,2012; Dunlop et al., 2013; Hanna and Hennebold, 2014) . It is possible that the ABVD combination or specific components activate these cells to form oocytes or oocyte like structures. Recent studies have shown that mesenchymal stem cells are sensitive to bleomycin treatment (Nicolay et al., 2016) , but nothing is known about how these drugs affect putative germline stem cells and other ovarian cells.
We also observed that post-ABVD tissue contains follicle clusters, many containing biovular and binucleate follicles, a feature more commonly associated with the prepubertal ovary . Follicles with more than one oocyte are reported during foetal development and in early life in many mammalian species (Papadaki, 1978; Telfer and Gosden 1987; Silva-Santos and Seneda, 2011) but are much rarer in adults (Turkalj et al., 2013) and may be preferentially lost with abnormal follicles during childhood . No biovular or binucleate follicles were observed in tissue from healthy women or following OEPA-COPDAC treatment highlighting that this difference in NGF patterning in the cortex of tissue is a result of the specific chemotherapy treatment. Furthermore, the in vitro developmental potential of ABVD-treated tissue showed differences compared to control tissue, with limited follicle development, comparable to that from prepubertal girls . We suggest that the lack of development in ABVD-treated tissue may be attributed to the inhibitory effect exerted by the high density of primordial follicles present (Da Silva-Buttkus et al., 2009). Initiation of follicle growth was observed in the obstetric patient cohort supporting the findings of previous studies .
In summary, this study demonstrates that ABVD treatment does not diminish the ovarian reserve and may paradoxically increase it. Other significant features such as the presence of biovular and binucleate oocytes and clustering are increased. In this respect, ABVD-exposed tissue is similar to that from prepubertal girls, and this similarity is also reflected in its reduced capacity for follicle development in vitro. The number of patients analysed is small, and so interpretation should be cautious. However, the data presented here have highlighted a phenomenon that has not been previously reported. Further investigation is required to elucidate the mechanism by which the ovarian reserve is affected by ABVD treatment, and the consequences for later fertility and reproductive lifespan.
